Raphael Teipel
Overview
Explore the profile of Raphael Teipel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
124
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Karp S, Trautmann-Grill K, Warncke P, Zolnowski D, Rollig C, Pannach M, et al.
Ann Hematol
. 2025 Feb;
PMID: 40000504
For patients (pts) with relapsed or refractory multiple myeloma (RRMM) after previous autologous hematopoietic cell transplantation (AHCT), novel agents, cellular and immunotherapies are increasingly available. Options for second-line treatment mostly...
2.
Jambor H, Ketges J, Otto A, von Bonin M, Trautmann-Grill K, Teipel R, et al.
J Am Med Inform Assoc
. 2025 Jan;
32(3):480-491.
PMID: 39820364
Objective: This study evaluated the legibility, comprehension, and clinical usability of visual timelines for communicating cancer treatment paths. We examined how these visual aids enhance participants' and patients' understanding of...
3.
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kroger N, et al.
Blood
. 2024 Jul;
144(14):1532-1542.
PMID: 39007722
Improved long-term survival rates after allogeneic hematopoietic cell transplantation (alloHCT) make family planning for young adult cancer survivors an important topic. However, treatment-related infertility risk poses challenges. To assess pregnancy...
4.
Epp K, Teipel R, Reuner U, Bornhauser M, Gunther C, Trautmann-Grill K
Br J Haematol
. 2024 Mar;
205(1):9-10.
PMID: 38471663
No abstract available.
5.
Teipel R, Rieprecht S, Trautmann-Grill K, Rollig C, Klotzer C, Zimmer K, et al.
Transfusion
. 2023 Oct;
63(11):2131-2139.
PMID: 37850414
Background: The incorporation of anti-CD38 monoclonal antibodies (mAb) in induction regimens of newly diagnosed transplant-eligible multiple myeloma (MM) patients has been established as a new standard. However, the optimal strategy...
6.
Osterhoff G, Kreinest M, Kuhnt T, Pohlenz C, Muller-Broich J, Rollig C, et al.
Global Spine J
. 2023 Apr;
13(1_suppl):85S-93S.
PMID: 37084345
Study Design: Mutlidisciplinary consensus recommendations for patients suffering from multiple myeloma (MM) involvement of the spinal column by the Spine Section of the German Association of Orthopaedic and Trauma Surgeons....
7.
Kruger T, Wehner R, Herbig M, Krater M, Kramer M, Middeke J, et al.
Front Immunol
. 2022 Oct;
13:1005554.
PMID: 36311725
Functional impairment of the bone marrow (BM) niche has been suggested as a major reason for prolonged cytopenia and secondary graft failure after allogeneic hematopoietic cell transplantation (alloHCT). Because mesenchymal...
8.
Teipel R, von Bonin M, Stolzel F, Schetelig J, Thiede C, Bornhauser M
Inn Med (Heidelb)
. 2022 Sep;
63(11):1126-1132.
PMID: 36149441
The detection of clonal hematopoiesis (CH) in patients with hematologic neoplasms who are undergoing a cellular therapy is common. The most frequently used cellular therapy procedures include autologous and allogeneic...
9.
Paiva B, Manrique I, Dimopoulos M, Gay F, Min C, Zweegman S, et al.
Blood
. 2022 Sep;
141(6):579-591.
PMID: 36130300
Measurable residual disease (MRD) evaluation may help to guide treatment duration in multiple myeloma (MM). Paradoxically, limited longitudinal data exist on MRD during maintenance. We investigated the prognostic value of...
10.
Sockel K, Stolzel F, Honl F, Baldauf H, Rollig C, Wermke M, et al.
Cancer Manag Res
. 2022 Feb;
14:547-559.
PMID: 35210852
Introduction: Allogeneic hematopoietic cell transplantation (HCT) during chemotherapy-induced aplasia may offer long-term survival in acute myeloid leukemia (AML) with otherwise poor prognosis including ELN adverse risk, relapsed or refractory disease....